Semaglutide vs Tirzepatide: Head-to-Head Evidence Compared

The SURMOUNT-5 trial (NCT05822830), published in the New England Journal of Medicine and led by Louis J. Aronne at Weill Cornell Medicine, is the only head-to-head Phase 3b comparison between these two drugs. The trial enrolled 751 adults with obesity across 32 sites in the US and Puerto Rico. Every number in the table below comes from published clinical trial data.

Feature	Semaglutide	Tirzepatide
Receptor targets	GLP-1 only (single agonist)	GLP-1 + GIP (dual agonist)
Brand names (obesity)	Wegovy (Novo Nordisk)	Zepbound (Eli Lilly)
Brand names (diabetes)	Ozempic, Rybelsus (Novo Nordisk)	Mounjaro (Eli Lilly)
Mean weight loss (SURMOUNT-5, 72 wks)	13.7% (15.0 kg)	20.2% (22.8 kg)
Achieved 25%+ weight loss	16.1% of participants	31.6% of participants
GI discontinuation rate (SURMOUNT-5)	5.6%	2.7%
Cardiovascular outcomes evidence	SELECT trial: 20% MACE reduction vs placebo	SURPASS-CVOT: non-inferiority vs dulaglutide (no placebo comparison)
Obesity dose range	1.7 mg or 2.4 mg weekly	10 mg or 15 mg weekly
Oral formulation available	Yes (Rybelsus for T2D; oral Wegovy 25 mg approved)	No
Branded monthly cost (US, without insurance)	~$1,300+	~$1,300+
Compounding status (May 2026)	503A available; 503B under proposed exclusion (April 2026)	503A available; 503B under proposed exclusion (April 2026)

The bottom line: Tirzepatide consistently outperforms semaglutide on weight loss and glycaemic endpoints in head-to-head data, while semaglutide holds the more mature cardiovascular evidence base.

The efficacy gap between these two drugs traces directly to their receptor pharmacology. Semaglutide is a GLP-1 receptor agonist only. Tirzepatide activates both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously, making it the first FDA-approved dual-agonist in its class. For full compound profiles, see the individual guides for semaglutide and tirzepatide.

GLP-1 activation drives appetite suppression via hypothalamic signalling, slows gastric emptying, and enhances glucose-dependent insulin secretion from pancreatic beta cells. These are the core effects shared by both drugs. What tirzepatide adds is GIP receptor activation, which appears to amplify the metabolic response through complementary pathways: improved fat oxidation, enhanced insulin sensitivity, and potentially different signalling dynamics in adipose tissue.

Importantly, tirzepatide binds the GLP-1 receptor with lower affinity than semaglutide and exhibits distinct signalling bias. This is not simply “semaglutide plus GIP” – it is a structurally different molecule with a different pharmacological profile at both receptors. A 2026 Nature Medicine study using 297,842 patient records found that these mechanistic differences may translate into different cardiovascular risk profiles, though the data remains observational.

The bottom line: Tirzepatide’s dual receptor activation is the mechanistic explanation for its superior weight loss and glycaemic results, but semaglutide’s stronger GLP-1 receptor affinity may explain its more mature cardiovascular signal.

SURMOUNT-5 is the only randomised trial directly comparing tirzepatide and semaglutide at their maximum tolerated obesity doses. The trial enrolled 751 adults (mean age 45, 35% male) with a BMI of 30+ (or 27+ with comorbidity) and no diabetes, across 32 US sites from April 2023 to November 2024.

At 72 weeks, tirzepatide produced a mean weight reduction of 20.2% (22.8 kg) compared with 13.7% (15.0 kg) for semaglutide. Tirzepatide was superior on all five key secondary endpoints. The proportions achieving weight loss thresholds tell the story clearly: 31.6% of tirzepatide participants lost at least 25% of their body weight versus 16.1% on semaglutide. Weight loss was approximately 6% lower in men than women in both treatment groups.

A notable finding often overlooked: gastrointestinal adverse events causing treatment discontinuation were more common with semaglutide (5.6%) than tirzepatide (2.7%). This challenges the common assumption that more potent weight loss comes with worse tolerability.

A 2025 meta-analysis in Cureus, pooling seven direct comparison studies with 28,980 participants (five observational, two RCTs), confirmed tirzepatide’s superiority. The pooled analysis showed a standardised mean difference of 0.75 (95% CI: 0.52 to 0.92), with significantly higher odds of reaching 10% weight loss on tirzepatide. High heterogeneity (I-squared greater than 90%) across studies reflects differences in populations, follow-up periods and dosing protocols.

The bottom line: Tirzepatide produced 47% more relative weight loss than semaglutide in their only head-to-head trial, with lower GI-related discontinuation rates – a combination of greater efficacy and better tolerability.

Semaglutide’s most significant advantage over tirzepatide is not weight loss – it is cardiovascular outcomes data. The SELECT trial (17,604 participants, mean follow-up 39.8 months) demonstrated that semaglutide reduced three-point major adverse cardiovascular events (MACE) by 20% compared with placebo in adults with established cardiovascular disease, a BMI of 27+ and no type 2 diabetes.

Tirzepatide does not yet have an equivalent result. The SURPASS-CVOT trial compared tirzepatide against dulaglutide (not placebo) and demonstrated non-inferiority for cardiovascular outcomes – meaning tirzepatide was shown to be no worse, but it was not designed to prove superiority in reducing cardiovascular events. A post-hoc analysis of SURMOUNT-5 published in European Heart Journal Open estimated greater projected 10-year cardiovascular risk reduction with tirzepatide based on improvements in blood pressure, cholesterol and other risk factors, but projected modelling is not the same as a completed outcomes trial.

For patients whose primary clinical concern is cardiovascular risk reduction alongside weight loss, semaglutide currently has the stronger evidence base. For patients whose primary goal is maximum weight reduction, tirzepatide has the clear edge. A 2026 Frontiers in Medicine narrative review concluded that “treatment selection should be individualised based on clinical priorities and patient characteristics” – which is the most honest summary of this comparison available.

The bottom line: Semaglutide has proven cardiovascular event reduction (SELECT trial, 20% MACE reduction); tirzepatide has shown cardiovascular non-inferiority against an active comparator but has not yet completed a placebo-controlled cardiovascular outcomes trial.

Both branded medications carry list prices above $1,000 per month in the US without insurance coverage. Insurance coverage varies significantly – many plans cover these drugs for type 2 diabetes but not specifically for weight loss, and prior authorisation requirements are common.

Compounding was a major access route when both drugs were on the FDA shortage list (tirzepatide added 2022, semaglutide added 2022), with compounded versions available at approximately $150-300 per month. The FDA declared the tirzepatide shortage resolved in October 2024 and semaglutide in February 2025. Since then, the compounding landscape has become a legal battleground. On 30 April 2026, the FDA proposed excluding both drugs (plus liraglutide) from the 503B Bulks List, which would eliminate the remaining regulatory pathway for large-scale outsourcing facility compounding.

The 503A patient-specific compounding pathway operates under a different legal framework and remains available as of May 2026, though the FDA has received more than 455 adverse event reports linked to compounded semaglutide and more than 320 linked to compounded tirzepatide, many involving dosing errors from multi-dose vials. For details on the compounding legal framework, see the 503A vs 503B explainer and the US legal overview.

The bottom line: Branded costs are comparable; compounded access is narrowing under regulatory pressure; the cost difference that drove the compounding market is disappearing as the FDA closes both shortage-based and bulks-list pathways.

Both drugs share a similar adverse event profile dominated by gastrointestinal side effects – nausea, vomiting, diarrhoea and constipation – that are generally mild to moderate and concentrated during dose escalation. In SURMOUNT-5, overall adverse event rates were comparable, but semaglutide produced more GI-related discontinuations (5.6% vs 2.7%).

Both drugs carry FDA-mandated warnings about thyroid C-cell tumours (observed in rodent studies), pancreatitis risk, and gallbladder-related events. Semaglutide has the longer post-marketing safety record, having been on the market since 2017 (Ozempic) compared to tirzepatide’s 2022 approval (Mounjaro). Semaglutide’s additional approved indications (MASH via ESSENCE trial, kidney outcomes via FLOW trial) also provide broader safety data across different patient populations.

The bottom line: Both share similar GI-dominant side effect profiles, but semaglutide has a longer post-marketing track record and broader safety data across more patient populations and indications.

Eli Lilly’s next-generation triple agonist retatrutide (GLP-1/GIP/glucagon) reported 28.3% mean weight loss at 80 weeks in the pivotal TRIUMPH-1 Phase 3 trial (May 2026), with participants reaching 30.3% at 104 weeks in an extension cohort. These numbers exceed both semaglutide and tirzepatide, but retatrutide is investigational and not FDA-approved as of May 2026. A head-to-head trial against tirzepatide (TRIUMPH-5) is enrolling now with results expected December 2026. For the full comparison, see tirzepatide vs retatrutide. For the compound profile, see the retatrutide research guide.

Is switching from semaglutide to tirzepatide likely to produce additional weight loss?

Based on the SURMOUNT-5 data and the meta-analysis evidence, tirzepatide consistently produces greater weight reduction at maximum doses. However, some patients show limited response to both drugs due to GLP-1 receptor biology (the GLP1R rs10305420 variant identified in the April 2026 Nature study). If a patient has failed to respond meaningfully to semaglutide at adequate doses with good adherence, a flat response to tirzepatide is possible. This is a clinical decision best made with a prescriber who can assess individual circumstances.

Has the FDA shortage resolution shut down compounded semaglutide and tirzepatide?

As of May 2026, patient-specific compounding under 503A remains available through licensed compounding pharmacies with a valid prescription. The 503B outsourcing facility pathway is under active regulatory pressure following the FDA’s April 2026 proposal to exclude both drugs from the 503B Bulks List. The legal landscape is evolving rapidly, and current access may change. Adverse event reports linked to compounded versions (455+ for semaglutide, 320+ for tirzepatide) underscore the importance of sourcing from reputable, licensed pharmacies.

Does semaglutide’s oral formulation change the comparison?

For patients who cannot or will not use injectable medications, semaglutide is currently the only option. Rybelsus (oral semaglutide for diabetes) has been available since 2019, and a higher-dose oral Wegovy 25 mg formulation has been approved for weight management. Tirzepatide is only available as a subcutaneous injection. Lilly’s oral incretin candidate (orforglipron) has been submitted to the FDA, but it is a separate compound, not oral tirzepatide.

Do men and women respond differently to these drugs?

Yes. In SURMOUNT-5, weight loss was approximately 6% lower in men than women in both treatment groups. The trial included 35% men, which is a higher proportion than most obesity trials. This sex-based difference has been observed across multiple GLP-1 class trials but is not yet fully explained mechanistically.